Why the study?
It is unclear whether antiarrhythmic medications administered during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest improve patient outcomes.
Does the use of antiarrhythmic drugs (amiodarone or lidocaine) improve patient outcomes in shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest?
Does the use of antiarrhythmic drugs (amiodarone or lidocaine) improve patient outcomes in shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest?
This AHA focused update recommends that either amiodarone or lidocaine may be considered for the treatment of shock-refractory ventricular fibrillation or pulseless ventricular tachycardia during cardiac arrest.
No takes yet. Share an insight, caveat, or question.
Antiarrhythmic benefit in shock-refractory VF/pVT arrest remains uncertain; leaves open the role of amiodarone or lidocaine in ACLS.
Panchal et al. (2018) conducted a review in Shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. Antiarrhythmic drugs (amiodarone or lidocaine) was evaluated on Patient outcomes. The 2018 AHA focused update recommends that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: